April 9th 2025
In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has important implications for urologists and the patients they treat.
Guidelines update: Bladder, kidney, prostate cancer
April 18th 2017This article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
18F-choline PET/CT detects PCa recurrences early
April 15th 2017Three out of four patients with prostate cancer with an 18F-choline positron emission tomography/computed tomography–detected recurrence were potentially salvageable with local therapy or metastasis-directed therapy (MDT), according to results of the screening phase of the phase II STOMP randomized trial.
Transgender surgery: Videos demonstrate cutting-edge techniques
In these videos, expert surgeons demonstrate robot-assisted penile inversion vaginoplasty, single-stage metoidioplasty, and simple orchiectomy for transgender patients.
Spacer system maintains QoL at 3 years post RT
March 23rd 2017Phase III study results suggest that a hydrogel spacer developed to separate the rectum and prostate during radiotherapy for prostate cancer works to maintain bowel and urinary quality of life and reduces late rectal toxicity by 78% at 3 years post radiotherapy.
Biomarkers predict metastasis, biochemical recurrence
March 22nd 2017Clinicians may soon be able to improve the risk stratification of men with prostate cancer with the help of a genomic classifier or a biopsy-based reverse transcription polymerase chain reaction assay, according to the results of two studies presented at the Genitourinary Cancers Symposium in Orlando, FL.
Novel assay may help identify prostate Bx candidates
March 22nd 2017A simple blood test that measures PSA structure rather than concentration may be more accurate than PSA in identifying men who need a prostate biopsy, according to the results of a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Hypofractionated IMRT outcomes comparable to standard regimen
March 20th 2017“We showed that we can safely compress radiation into a shorter time frame, into fewer treatments, at higher dose per fraction, with similar clinical outcomes and similar toxicity profiles,” said researcher Michael Wang, MD.
Testosterone therapy's big week: One urologist's perspective
March 16th 2017Abraham Morgentaler, MD, shares why the recent publication of five studies on testosterone therapy in JAMA and JAMA Internal Medicine "was arguably the most important week ever for the science of testosterone therapy and its impact on men's health."
Testis Ca care deviates from guidelines in 30% of patients
March 1st 2017Nearly one-third of men with testicular cancer undergo diagnostic or therapeutic interventions that are at odds with guidelines from the National Comprehensive Cancer Network (NCCN), according a study published in the Journal of Urology (2017; 197:684-9).
When is a patient cured after prostatectomy?
February 1st 2017"Rather than making a blanket statement regarding continued follow-up, we need to consider the pathologic features commonly known to increase the risk of [prostate cancer] recurrence-concurrent medical problems, the patient’s age at recurrence, PSA doubling time, longevity in the family, etc," writes J. Brantley Thrasher, MD.
Biochemical recurrence risk high 10 years post-RP
February 1st 2017The risk for biochemical recurrence of prostate cancer remains relatively high even 10 years after radical prostatectomy, but it does not appear to be influenced by a positive family history of prostate cancer or a family or personal history of other cancer, according to a study analyzing data from the prospective German Familial Prostate Cancer database.